Brentuximab vedotin (Adcetris)

General information

Class/mechanism: Anti-CD30 antibody (brentuximab) with protease-cleavable linker to chemotherapeutic agent (monomethyl auristatin E (MMAE, vedotin)). The antibody-drug complex binds to CD30 expressing cells and is internalized, where the active chemotherapeutic agent MMAE is released via proteolytic cleavage of the antibody-drug linker. MMAE is a microtubule disrupting agent that interferes with mitosis, causes cell cycle arrest, and eventual apoptosis.
Route: IV
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape,UpToDate (courtesy of Lexicomp), or the prescribing information.

Diseases for which it is used

• Anaplastic large cell lymphoma
• Diffuse large B-cell lymphoma
• Hodgkin lymphoma
• Mediastinal gray-zone lymphoma
• Primary mediastinal B-cell lymphoma

Patient drug information

• Brentuximab vedotin (Adcetris) patient drug information (Chemocare)
• Brief patient counseling information can be found on page 15 of the package insert
• Brentuximab vedotin (Adcetris) patient drug information (UpToDate)

History of changes in FDA indication

• 8/19/2011: Granted FDA accelerated approval for:

1. Treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates.
2. Treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen.

Also known as

SGN-35 and cAC10-vcMMAE.